Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real‐world analysis of outcomes in 211 patients

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

(2020) Sasanka M. Handunnetti et al.   BLOOD

Efficacy of R‐BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy

(2020) Rory McCulloch et al.   BRITISH JOURNAL OF HAEMATOLOGY

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

(2020) Michael Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma

(2020) David A. Bond et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study

(2020) Carlo Visco et al.   LEUKEMIA

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

(2019) Peter Martin et al.   BLOOD

Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up

(2019) Simon Rule et al.   BLOOD

Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party

(2018) Stephen P. Robinson et al.   BONE MARROW TRANSPLANTATION

Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN)

(2018) Alexandra Smith et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

(2018) Constantine S. Tam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

(2018) Mats Jerkeman et al.   Lancet Haematology

Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death

(2018) Carlo Visco et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow-up from a pooled analysis

(2018) Simon Rule et al.   HAEMATOLOGICA

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study

(2018) Matthew S Davids et al.   Lancet Haematology

Postibrutinib outcomes in patients with mantle cell lymphoma

(2016) P. Martin et al.   BLOOD

Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients

(2016)   HAEMATOLOGICA

Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients

(2016)   HAEMATOLOGICA

Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study

(2014) A. Abrahamsson et al.   BLOOD

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE